← Evidence map

TrialJCO precision oncology2025

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. | Socratic